Fig. 3: Prognostic impact of high MIPI-c or high p53 expression on overall survival stratified by treatment groups of the MCL Younger and the MCL Elderly trial. | Leukemia

Fig. 3: Prognostic impact of high MIPI-c or high p53 expression on overall survival stratified by treatment groups of the MCL Younger and the MCL Elderly trial.

From: Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

Fig. 3

Kaplan–Meier estimates of OS among patients treated with R-CHOP induction and aPBSCT (A), alternating R-CHOP/R-DHAP induction and aPBSCT (B), R-FC and IFN maintenance (C) and R-CHOP + R maintenance (D) stratified by the presence of high MIPI-c or p53 expression >50% (high-risk disease) compared to low, low-intermediate or high-intermediate MIPI-c and p53 expression <50% (low-risk disease). The number at risk is based on all classifiable patients.

Back to article page